David Cosman
Direktor/Vorstandsmitglied bei Aequus BioPharma, Inc.
Profil
David Cosman is currently a Director at Aequus BioPharma, Inc. He previously worked as a Research Director at Amgen, Inc. and as a Vice President-Molecular Biology at Immunex Corp.
Aktive Positionen von David Cosman
| Unternehmen | Position | Beginn |
|---|---|---|
Aequus BioPharma, Inc.
 Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Direktor/Vorstandsmitglied | 17.09.2009 |
Ehemalige bekannte Positionen von David Cosman
| Unternehmen | Position | Ende |
|---|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | 14.07.2009 |
| AMGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Health Services |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
